IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Novateor Research Laboratories Ltd IPO is a Fixed Price listing on BSE SME exchange. The company is based in Ahmedabad and caters to Healthcare - Personal Care sector. First Overseas Capital is the merchant banker of Novateor Research Laboratories Ltd IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 27th July 2019.
Novateor Research Laboratories Ltd IPO posted revenues of ₹ 0.51 crores and PAT of ₹ 0.22 crores in FY19 on annualised basis.
Revenue:
₹ 0.40 Cr.
EBITDA Margin:
97.50
% 
Net Worth: ₹ 4.07 Cr.
Market Capitalisation:
[●]
P/E:
52.00 times
P/BV: [●]
EV/EBITDA: [●]
Financial results of Novateor Research Laboratories Ltd IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Mar-19 | FY18 | FY17 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 4.31 | 1.83 | 1.89 | ||
| Net Worth | 4.07 | 0.92 | 0.92 | ||
| Total Debt | 0.01 | 0.01 | 0.04 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
0.40
0.40 |
0.09 | 0.13 | ||
EBITDA
EBITDA on annualised basis |
0.39
0.39 |
0.07 | 0.07 | ||
PAT
PAT on annualised basis |
0.21
0.21 |
[●] | [●] | ||
Novateor Research Laboratories Ltd IPO PAT Margin is 52.50 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Novateor Research Laboratories Ltd IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Mar-19 | FY18 | FY17 |
|---|---|---|---|
| EBITDA Margin (%) | 97.50 | 77.78 | 53.85 |
| PAT Margin (%) | 52.50 | [●] | [●] |
| EPS (₹) | 0.74 | 0.01 | -0.03 |
| ROE (%) | 5.16 | [●] | [●] |
| ROCE (%) | [●] | [●] | [●] |
| ROA (%) | 4.87 | [●] | [●] |
| Debt to Equity | 0.00 | 0.01 | 0.04 |
The market Capitalisation of Novateor Research Laboratories Ltd IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Novateor Research Laboratories Ltd IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Novateor Research Laboratories Ltd IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Novateor Research Laboratories Ltd IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Novateor Research Laboratories LtdIPO has a Price-to-Earnings (PE) ratio of 52.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Novateor Research Laboratories Ltd IPO reported revenue of ₹ 0.51 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Novateor Research Laboratories Ltd IPO provide insights into sales growth, market demand, and business scalability.
Novateor Research Laboratories Ltd recorded an EBITDA of ₹ 0.39 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Novateor Research Laboratories Ltd Profit After Tax (PAT) is ₹ 0.21 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 0.40 Cr.
EBITDA Margin:
97.50
%
Net Worth: ₹ 4.07 Cr.
Market Capitalisation:
[●]
P/E:
52.00 times
P/BV: [●]
EV/EBITDA: [●]
Novateor Research Laboratories Ltd operates in Healthcare - Personal Care and . The Issue is listed on BSE SME in Sep, 2019. Novateor Research Laboratories Ltd IPO size was 4.49 with Issue price of 24.00 .
Merchant Banker(s) of Novateor Research Laboratories Ltd IPO: First Overseas Capital Limited
Novateor Research Laboratories Ltd IPO subscription was 1.24 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Novateor Research Laboratories Ltd IPO listed at a listing price of 24.15 against the offer price of 24.00.
The current market price of Novateor Research Laboratories Ltd is 41.90.
Why Us?
